Leo Pharma sells development program, becomes shareholder of Swedish biotech buyer

Swedish biotech firm Aqilion has acquired a phase-1 ready candidate from Leo Pharma, and the firm is aiming to address a high unmet medical need in the form of the inflammation disease, eosinophilic esophagitis. Through the deal, Leo Pharma also becomes a shareholder of Aqilion.

Leo Pharma sells phase-I ready drug candidate and becomes a shareholder in Swedish buyer Aqilion | Photo: Leo Pharma / PR

International attention continues to be fixed on Leo Pharma, which saw its CEO Catherine Mazzacco step down with immediate effect last week.

The skin specialists from Copenhagen have managed to stir up interest in its JAK inhibitor Leo 142397 at Swedish Aqilion. So much so that they company is buying all of the program's rights, which is ready for human testing, Aqilion announces in a press release.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Rumored GN purchase unlikely but not impossible, say analysts

A low value assessment, a high structural value, and no dominant shareholders make GN Group a reasonable investment case for international private equity firms and industrial players. But just how likely is it? Analysts reveal their best bets for what a GN acquisition could look like.

New CFO wants to shake things up at WSA

A mere month into her new job, Marianne Wiinholt, WS Audiology’s fifth chief financial officer since the firm was established through a merger in 2019, is heralding great structural changes.

Further reading

Related articles

Latest news

See all jobs